Paper published in a journal (Scientific congresses and symposiums)
Pharmacokinetic (PK) effects and safety of olaparib in combination with tamoxifen, anastrozole or letrozole : Phase I study
Plummer, R.; Verheul, H.M.; Langenberg, M. et al.
2016 • In Journal of Clinical Oncology, 34, p. 2562
Peer Reviewed verified by ORBi
 

Files


Full Text
Pharmacokinetic effects and safety of olaparib in combination ... abstract.pdf
Publisher postprint (812.87 kB)
Request a copy
Annexes
Pharmacokinetic effects and safety of olaparib in combination ... - poster 2.pdf
Publisher postprint (164.39 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
oncology
Disciplines :
Oncology
Author, co-author :
Plummer, R.
Verheul, H.M.
Langenberg, M.
Leunen, K.
Molife, L.R.
Rolfo, Ch.
Grundtvig-Soerensen, P.
De Greve, J.
Rottey, S.
JERUSALEM, Guy  ;  Centre Hospitalier Universitaire de Liège - CHU > Service d'oncologie médicale
Itiliano, A.
Spicer, J.
Dirix, L.
Goessl, C.
Birkett, J.
Spencer, S.
Learoyd, M.
Dean, E.
More authors (8 more) Less
Language :
English
Title :
Pharmacokinetic (PK) effects and safety of olaparib in combination with tamoxifen, anastrozole or letrozole : Phase I study
Publication date :
2016
Event name :
2016 ASCO Annual Meeting
Event place :
Chicago, United States
Event date :
June 3-7, 2016
Audience :
International
Journal title :
Journal of Clinical Oncology
ISSN :
0732-183X
eISSN :
1527-7755
Publisher :
American Society of Clinical Oncology, Alexandria, United States - Virginia
Volume :
34
Pages :
abstract 2562
Peer review/Selection committee :
Peer Reviewed verified by ORBi
Available on ORBi :
since 05 July 2016

Statistics


Number of views
217 (2 by ULiège)
Number of downloads
3 (2 by ULiège)

Bibliography


Similar publications



Contact ORBi